<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15591">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903914</url>
  </required_header>
  <id_info>
    <org_study_id>CX-1158-101</org_study_id>
    <nct_id>NCT02903914</nct_id>
  </id_info>
  <brief_title>Arginase Inhibitor CB-1158 in Patients With Solid Tumors</brief_title>
  <official_title>Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in
      combination with immune checkpoint therapy in patients with advanced/metastatic solid
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in
      combination with immune checkpoint therapy in patients with advanced/metastatic solid
      tumors.

      Single Agent CB-1158:

      Patients with advanced/metastatic solid tumors be enrolled into escalating monotherapy dose
      cohorts to determine the Recommended Phase 2 Dose (RP2D) of CB-1158. Additional patients
      with NSCLC, CRC, and other tumors will be enrolled at the single agent RP2D.

      Combination Treatment:

      Patients with advanced/metastatic clear cell renal cell carcinoma, melanoma, and non-small
      cell lung cancer and other solid tumors previously treated with a PD-1 and PD-L1 therapy
      will be enrolled into separate cohorts of combination therapy (CB-1158 and nivolumab) to
      determine the RP2D. Additional patients with NSCLC and melanoma will be enrolled at the
      combination of CB-1158 with nivolumab at the RP2D.

      All patients will be assessed for safety, pharmacokinetics, biomarkers and tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of CB-1158 as a single agent and in combination with nivolumab: Incidence of Adverse Events</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
    <description>Evaluation of adverse events (AEs) and changes in laboratory values, vital signs, and physical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) of CB-1158</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Up to 30 patients with solid tumors will be enrolled in Dose Escalation to determine the RP2D of CB-1158 as monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RP2D of CB-1158 with Nivolumab</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Up to 24 patients with solid tumors will be enrolled in Dose Escalation to determine the RP2D of CB-1158 with Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of CB-1158</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
    <description>Non-compartmental method of analysis will be used to analyze the plasma concentrations of CB-1158</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Colo-Rectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Squamous-cell Carcinomas of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Monotherapy Dose Escalation Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy Cohort 1a: CB-1158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-1158 Monotherapy expansion in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy Cohort 2a: CB-1158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR negative)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-1158 as Monotherapy expansion in CRC After SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy Cohort 2b: CB-1158 administered orally at the RP2D in patients with advanced/metastatic RCC previously treated with SOC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-1158 as Monotherapy in Tumors with High Granulocytic MDSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy Cohort 2c: CB-1158 administered orally at the RP2D in patients with tumors High Granulocytic MDSCs or neutrophils; this includes squamous cell carcinoma of the head and neck (SCCHN), renal cell cancer (RCC), gastric or gastroesophageal junction (GEJ) cancer, urothelial cell cancer (UCC), and melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1 Combination Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Cohort 1b: CB-1158 and full dose nivolumab administered in patients with advanced/metastatic NSCLC, RCC and Melanoma. Up to 6 dose levels (200 - 1000 mg) will be explored to determine the recommended phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1 Combination in NSCLC Prior PD-1/PD-L1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 Combo Cohort 3a: CB-1158 and nivolumab at the combination RP2D administered in patients with advanced/metastatic NSCLC previously treated with a PD-1 and/or PD-L1 therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1 Combination in MEL Prior PD-1/PD-L1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-Combo Cohort 3b: CB-1158 and nivolumab at the combination RP2D administered in patients with advanced/metastatic Melanoma previously treated with a PD-1 and/or PD-L1 therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-1158</intervention_name>
    <description>Arginase Inhibitor</description>
    <arm_group_label>Monotherapy Dose Escalation Solid Tumors</arm_group_label>
    <arm_group_label>CB-1158 Monotherapy expansion in NSCLC</arm_group_label>
    <arm_group_label>CB-1158 as Monotherapy expansion in CRC After SOC</arm_group_label>
    <arm_group_label>CB-1158 as Monotherapy in Tumors with High Granulocytic MDSCs</arm_group_label>
    <arm_group_label>PD-1 Combination Dose Escalation</arm_group_label>
    <arm_group_label>PD-1 Combination in NSCLC Prior PD-1/PD-L1</arm_group_label>
    <arm_group_label>PD-1 Combination in MEL Prior PD-1/PD-L1</arm_group_label>
    <other_name>Arginase Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>PD-1 Inhibitor</description>
    <arm_group_label>PD-1 Combination Dose Escalation</arm_group_label>
    <arm_group_label>PD-1 Combination in NSCLC Prior PD-1/PD-L1</arm_group_label>
    <arm_group_label>PD-1 Combination in MEL Prior PD-1/PD-L1</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        *Additional cohort specific criteria may apply

        Inclusion Criteria:

          -  Ability to provide written informed consent in accordance with federal, local, and
             institutional guidelines

          -  Histological or cytological diagnosis of metastatic cancer or locally advanced cancer
             that is not amenable to local therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Life Expectancy of at least 3 months

          -  Adequate hepatic, renal, cardiac, and hematologic function

          -  Measurable disease by RECISTv1.1 criteria

          -  Resolution of treatment-related toxicities

        Exclusion Criteria:

          -  Unable to receive oral medications

          -  Unable to receive oral or IV hydration

          -  Intolerance to prior anti-PD-1/PD-L1 therapy

          -  Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)

          -  Any other current or previous malignancy within 3 years except protocol allowed
             malignancies

          -  Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal
             therapy within 2 weeks

          -  Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note:
             some cohort exceptions allow anti-PD-1 therapy)

          -  Active known or suspected exclusionary autoimmune disease

          -  Any condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily
             prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks

          -  History of known risks factors for bowel perforation

          -  Symptomatic ascites or pleural effusion

          -  Major surgery within 28 days before Cycle 1 Day 1

          -  Active infection requiring within 2 weeks prior to first dose of study drug

          -  Patients who have HIV, Hepatitis B or C

          -  Conditions that could interfere with treatment or protocol-related procedures

          -  Active, non-stable brain metastases or CNS disease

          -  Known deficiencies or suspected defect in the urea cycle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith W Orford, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Oncology Hematology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Althoff</last_name>
      <phone>480-860-5000</phone>
    </contact>
    <investigator>
      <last_name>Frank Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhang, MD, PhD</last_name>
      <phone>713-794-3601</phone>
    </contact>
    <investigator>
      <last_name>Siqing Fu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5252</phone>
      <email>isabel.jimenez@start.stoh.com</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Smetzer, BSN, RN, OCN</last_name>
      <phone>210-593-5269</phone>
      <email>leslie.smetzer@start.stoh.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>September 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Checkpoint Inhibitors</keyword>
  <keyword>Tumor Metabolism</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>PD-L1 inhibitor</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>RCC</keyword>
  <keyword>MEL</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Arginase</keyword>
  <keyword>Arginase Inhibitor</keyword>
  <keyword>CB-1158</keyword>
  <keyword>SCCHN</keyword>
  <keyword>GEJ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
